4/19/2023 0 Comments Twist bioscienceA significant constraint in many NGS applications has been the high cost and long turnaround time of oligonucleotide production.Twist attributes the growth of their NGS tools segment to emerging use cases such as population-scale sequencing, liquid biopsies, minimal residual disease testing, and single-cell sequencing. Credit: Twist Bioscience (CAGR numbers by Nanalyze)Īs it turns out, creating synthetic DNA isn’t nearly in demand as much as creating NGS tools which Twist sells through a direct sales team focused on the NGS tools market which is entirely separate from their synthetic DNA sales force. But why are SynBio revenues growing much slower than NGS revenues? Here are the compound annual growth rates ( CAGRs) for each of Twist’s defined revenue segments over the past several years – synthetic genes, oligo pools, DNA and biopharma libraries, and next- generation sequencing ( NGS) tools. There was one major customer who accounted for 17% of our revenue for the financial year ended September 30, 2019.įrom these bullet points, we can deduce that Ginkgo’s business is decreasing as a percentage of Twist Bioscience’s total revenues which is great ( reduced customer concentration risk).There were two major customers who accounted for 12% and 10% of our revenue for the fiscal year ended September 30, 2020.No major customer accounted for 10% or more of our revenue for the fiscal year ended September 30, 2021.They’ve also removed any mention of Ginkgo Bioworks being a key customer in their SEC filings, and don’t even mention that as a risk factor anymore per their recently filed 10-K. Notice how they recently stopped breaking out revenues for Ginkgo Bioworks – one of their biggest customers – something that was useful to know. Credit: Twist BioscienceĪside from showing consistent quarterly revenue growth over the past three years, this chart contains other useful insights. Indeed, we see this to be the case over time. Therefore, Twist Bioscience is a pick-and-shovel play on synthetic biology tools that should grow along with the entire synbio industry. The need for this service has expanded significantly with the emergence of synthetic biology. For example, Twist Bioscience Corporation ( TWST) is a company that produces synthetic DNA strands on demand for their clients. In addition to monitoring revenue growth, it’s good to have an elevator pitch that quickly articulates your bull thesis. Is a company able to monetize their technology and capture market share in a large total addressable market ( TAM)? Revenue growth is the one metric that cuts through all the noise and distills it down to what’s most important for a disruptive technology stock. In this seminar, you will learn how Twist Exome 2.There’s always a delicate balance between being too hands on with a stock and not paying close enough attention to how its business evolves. Ananth Bommakanti will provide a full overview of Exome 2.0, revealing how it helps alleviate common sequencing pitfalls and provides researchers with best-in-class sequencing efficiency, on-target rate, duplicate rate, and mean target coverage - all while delivering clinically relevant content known today. In this webinar, Twist Biosciences Senior Field Application Scientist, Dr. With superior coverage of major genetic databases, inclusion of clinically relevant pathogenic variants, high uniformity, and low off-target rate, it eliminates compromise between performance and target inclusion. Exome 2.0, designed to detect rare and inherited diseases and germline cancers, is the latest addition to our robust and ever advancing NGS target enrichment portfolio. ![]() ![]() Please join us on November 30 as we introduce the new Twist Exome 2.0 target enrichment panel.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |